Sorafenib for Hepatopulmonary Syndrome

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this clinical trial is to determine the safety and effects of the study drug, sorafenib, in adults diagnosed with hepatopulmonary syndrome (HPS). The study will evaluate how well the drug is tolerated and its effect on the level of oxygen in the blood and the function of the lung vessels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

NCT02128958

Hepatocellular Carcinoma

COMPLETED PHASE2

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects

NCT02095587

Hepatic Impairment

COMPLETED PHASE1

To Study the Safety and Efficacy of Simvastatin in Patients With Hepatopulmonary Syndrome in Cirrhosis.

NCT05187715

Liver Cirrhosis

UNKNOWN NA

Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects

NCT00812305

Pain Hepatic Impairment

COMPLETED PHASE1

A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

NCT02927314

Non-alcoholic Steatohepatitis (NASH)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatopulmonary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sorafenib

400 mg (2 capsules) taken by mouth once a day

Group Type EXPERIMENTAL

Sorafenib

Intervention Type DRUG

Sorafenib is a kinase inhibitor indicated for the treatment of:

* Unresectable hepatocellular carcinoma
* Advanced renal cell carcinoma
* Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment

Placebo

2 capsules taken by mouth once a day

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sorafenib

Sorafenib is a kinase inhibitor indicated for the treatment of:

* Unresectable hepatocellular carcinoma
* Advanced renal cell carcinoma
* Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nexavar

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of HPS:

1. AaPO2 ≥ 15 mm Hg (≥ 20 mm Hg for age \> 64 yrs)
2. Intrapulmonary shunting
3. Absence of significant restriction (TLC \< 70%) or obstruction (FEV1 \< 80% \& FEV1/FVC \< 70%)
4. Presence of cirrhosis/hepatic fibrosis and/or portal hypertension
* Child-Pugh class A or B liver disease
* Platelet count ≥ 30 ×10e9 per liter
* Hemoglobin ≥ 8.5 g per deciliter
* International normalized ratio ≤ 2.3
* Albumin ≥ 2.8 g per deciliter
* Total bilirubin ≤ 5 mg per deciliter
* Alanine aminotransferase and aspartate aminotransferase ≤ 5 times the upper limit of the normal range
* Serum creatinine ≤ 1.5 times the upper limit of the normal range and not receiving dialysis
* Negative pregnancy test (for women of childbearing potential) at both screening and baseline visits. Post-menopausal women (defined as no menses for one year) and surgically sterilized women are not required to undergo a pregnancy test.
* Subjects (men and women) of childbearing potential must agree to use medically acceptable contraception beginning at the signing of the Informed Consent Form until at least 14 days after the last dose of study drug.
* Age ≥ 21 years
* Ability to provide informed consent

Exclusion Criteria

* Recent chronic heavy alcohol consumption
* Enrollment in a clinical trial or concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 28 days of screening visit
* Current hepatic encephalopathy
* Active infection
* Diagnosis of portopulmonary hypertension
* WHO Class IV functional status
* Congenital long-QT syndrome
* Subjects who have used strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, phenobarbital, St. John's Wort \[Hypericum perforatum\], dexamethasone at a dose of greater than 16 mg daily, or rifampin \[rifampicin\], and/or rifabutin) within 28 days before randomization
* Subjects who are currently taking Coumadin®(warfarin)
* Active or clinically significant cardiac disease, including:

1. Active coronary artery disease
2. Unstable angina (anginal symptoms at rest), new-onset angina within 12 weeks before randomization, or myocardial infarction within 24 weeks before randomization
* Liver or other solid organ transplant recipients
* Expectation of liver transplant within four months of randomization
* Hepatocellular carcinoma that does not meet all of the following criteria:

1. Single lesion ≤ 3 cm documented by LIRADS criteria
2. Complete response to ablative therapy (TACE, RFA, alcohol ablation) using the modified RECIST criteria one month after therapy with no more than two treatments
3. No other lesions develop after initiation of HCC therapy
* Uncontrolled hypertension (systolic pressure \>140 mm Hg or diastolic pressure \> 90 mm Hg on repeated measurement) despite optimal medical management.
* Any hemorrhage/bleeding event of NCI-Common Toxicity Criteria for Adverse Effects v4.0 Grade 3 or higher within 4 weeks before randomization
* Presence of a non-healing wound, non-healing ulcer, or bone fracture
* Women who are pregnant or breast-feeding
* Major surgery 28 days prior to randomization
* Subjects with any previously untreated or concurrent cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor. Subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before randomization are allowed. All cancer treatments (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) must be completed at least 3 years prior to study entry (i.e., signature date of the informed consent form).
* Inability to comply with the protocol and/or not willing or not available for follow-up assessments

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No